Literature DB >> 27510170

A novel TBX20 loss‑of‑function mutation contributes to adult‑onset dilated cardiomyopathy or congenital atrial septal defect.

Yi-Meng Zhou1, Xiao-Yong Dai1, Ri-Tai Huang2, Song Xue2, Ying-Jia Xu3, Xing-Biao Qiu3, Yi-Qing Yang3.   

Abstract

Dilated cardiomyopathy (DCM) is the most prevalent form of primary cardiomyopathy in humans and is a leading cause of heart failure and sudden cardiac death. Genetic abnormalities have been demonstrated to be a major contributor to the development of DCM. However, DCM is a genetically heterogeneous disease, and the genetic basis underlying DCM in a significant proportion of patients remains unclear. In the current study, the coding exons and splicing junction sites of the T‑Box 20 (TBX20) gene, which encodes a T‑box transcription factor essential for cardiac morphogenesis and structural remodeling, were sequenced in 115 unrelated patients with idiopathic DCM, and a novel heterozygous mutation, p.E143X, was identified in one patient. Genetic analysis of the mutation carrier's pedigree indicated that the nonsense mutation was present in all the living family members with DCM, and also in a female patient with a congenital atrial septal defect. The mutation, which was predicted to generate a truncated protein with only the N‑terminus and a fraction of the T‑box domain remaining, was absent in 800 control chromosomes. Functional assays using a dual‑luciferase reporter assay system revealed that the truncated TBX20 protein had no transcriptional activity in contrast to its wild‑type counterpart. Furthermore, the mutation abolished the synergistic activation between TBX20 and NK2 homeobox 5, or between TBX20 and GATA binding protein 4. The observations of the current study expand the mutation spectrum of TBX20 associated with DCM and congenital heart disease (CHD), which provide novel insight into the molecular mechanisms underlying DCM and CHD, suggesting the potential implications for the effective and personalized treatment of these diseases.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27510170     DOI: 10.3892/mmr.2016.5609

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  6 in total

Review 1.  Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association.

Authors:  Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

2.  A Novel MEF2C Loss-of-Function Mutation Associated with Congenital Double Outlet Right Ventricle.

Authors:  Cai-Xia Lu; Wei Wang; Qian Wang; Xing-Yuan Liu; Yi-Qing Yang
Journal:  Pediatr Cardiol       Date:  2018-02-21       Impact factor: 1.655

Review 3.  Understanding the molecular basis of cardiomyopathy.

Authors:  Marie-Louise Bang; Julius Bogomolovas; Ju Chen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-11-19       Impact factor: 5.125

4.  DNA methylation status of TBX20 in patients with tetralogy of Fallot.

Authors:  Juan Gong; Wei Sheng; Duan Ma; Guoying Huang; Fang Liu
Journal:  BMC Med Genomics       Date:  2019-05-28       Impact factor: 3.063

Review 5.  Genetics of congenital heart disease: a narrative review of recent advances and clinical implications.

Authors:  Jun Yasuhara; Vidu Garg
Journal:  Transl Pediatr       Date:  2021-09

6.  MEF2C loss-of-function mutation contributes to congenital heart defects.

Authors:  Xiao-Hui Qiao; Fei Wang; Xian-Ling Zhang; Ri-Tai Huang; Song Xue; Juan Wang; Xing-Biao Qiu; Xing-Yuan Liu; Yi-Qing Yang
Journal:  Int J Med Sci       Date:  2017-09-08       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.